WCWei Cui

Wei Cui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Cui has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Yibin Zhao

    Department of Colorectal Surgery, Ningbo Medical Center Lihuili Hospital (Affiliated Lihuili Hospital of Ningbo University) Ningbo, China

    3 shared publications
  • Jie Shen

    Department of Colorectal Surgery, Ningbo Medical Center Lihuili Hospital (Affiliated Lihuili Hospital of Ningbo University) Ningbo, China

    2 shared publications
  • Jie Sheng

    Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China

    2 shared publications
  • Yibing Zhao

    Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China

    2 shared publications
  • Dan Ye

    Geriatrics Department, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China

    1 shared publication
  • Fanggui Shao

    Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Southern Baixiang, OuHai District, Wenzhou, Zhejiang, People's Republic of China.

    1 shared publication

Latest Publications

  • Open Access

    Tertiary lymphoid structure-related genes drive tumor microenvironment heterogeneity and prognostic disparities in left- vs. right-sided colon cancer

    by Hongyi Zhou, Xiaohong Qian, Qiujun Dai, Qiqi Zhu, Peiyuan Li, Wei Cui, Yibin Zhao

    Background: Colorectal cancer (CRC) exhibits significant heterogeneity between left-sided (LCC) and right-sided (RCC) subtypes, influenced by tertiary lymphoid structures-related genes (TLSRGs). This study aimed to explore TLSRGs’ roles in LCC/RCC differences, including expression, mutations, prognosis, and molecular pathways, while developing a prognostic risk model. Methods: Data were integrated from The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) (324 samples: 135 LCC, 189 RCC) and Gene Expression Omnibus (GEO) datasets. TLSRGs were analyzed for differential expression, mutations, and prognostic associations using Wilcoxon tests, Cox regression, and gene set variation analysis (GSVA). Consensus clustering identified molecular subtypes. Single-cell analysis involved Seurat/Harmony for clustering and annotation, single-sample gene set enrichment analysis (ssGSEA) for scoring, and CellChat for cell communication. A machine learning-based risk model was constructed by screening ten algorithms (including SuperPC, RSF, CoxBoost, etc.) using the Mime package. The SuperPC algorithm demonstrated the best performance and was built on TLSRGs and related pathways, validated via Concordance index (C-index), Kaplan-Meier (KM) curves, and receiver operating characteristic (ROC) analysis. Results: Integrated analysis revealed significant heterogeneity between LCC and RCC, characterized by distinct somatic mutation profiles, differential expression of 27 TLSRGs, and subtype stratification via TLSRG-based consensus clustering (C1 enriched in RCC, PFBLN7 [hazard ratio (HR) =7.09 for disease-specific survival (DSS)] and MS4A1 [HR =7.79 for disease-free interval (DFI)] predicted poor survival in LCC, while ICOS was protective in RCC [HR =0.42 for overall survival (OS)]. Drug sensitivity screening identified 22 agents with differential half-maximal inhibitory concentration (IC50) correlated to TLSRG expression, and immune infiltration analysis revealed reduced CD8+ T cells/follicular helper T cells in RCC. An 8-gene prognostic signature (HSPB1, NCOR2, STIL, etc.) derived via SuperPC effectively stratified high-risk patients in TCGA (HR =2.06, P=0.001) and GSE103479 (HR =1.86, P=0.02), with consistent performance across LCC/RCC subgroups. Conclusions: TLSRGs underpin LCC/RCC heterogeneity in mutations, expression, immunity, and cell interactions. The developed risk model offers robust prognostic value, highlighting potential therapeutic targets for sidedness-specific CRC management.


  • Open Access

    FOXK1 drives colorectal cancer progression by transcriptionally activating GRB2

    by Yu Wang, Jianan Wang, Dan Ye, Shaohui Yang, Wei Cui

    Colorectal cancer (CRC) represents a leading cause of global cancer-related mortality. Despite substantial therapeutic advancements, persistent challenges


  • DNA centipede nanowires drive rapid picomolar microRNA detection in cells and serum

    by Zhixiong Dong, Yangyang Liu, Zhiwei Zhu, Xianghan Song, Huo Xu, Wei Cui, Fanggui Shao


  • Open Access

    Immunological microenvironment differences between left and right colon cancer: dynamic interactions of CASC15+KLK6+ epithelial subpopulation with T cells and mast cells

    by Yibin Zhao, Hao Liu, Yu Wang, Jie Shen, Yang Le, Peiyuan Li, Yuxiang Zhao, Feng Gao, Wei Cui

    Background: Right-sided colon cancer (RCC) and left-sided colon cancer (LCC) exhibit distinct clinical behaviors and molecular characteristics, but immune microenvironmental differences remain unclear. Methods: Single-cell RNA sequencing was performed on three LCC and three RCC tumors. Validation studies included immunofluorescence on 70 patients (30 LCC and 40 RCC). Analytical methods comprised cellular heterogeneity assessment (Seurat, inferCNV), pseudotime trajectory reconstruction (Monocle2), pathway enrichment (GSVA), and cell-cell communication inference (CellChat). Results: RCC displayed significantly increased exhausted CD8 + T cells and decreased activated CD8 + T cells compared to the LCC. Concurrently, RCC showed reduced proportions of TNF + mast cells (MCs) and increased VEGFA + MCs. We identified a CASC15 + KLK6 + epithelial subpopulation specifically enriched in RCC tumors, exhibiting high copy number variation scores, elevated malignant pathway activity, and a significant negative correlation with patient survival (r = − 0.2919, p = 0.0142). Enhanced intercellular communication involving MIF signaling (CD74/CXCR4/CD44) and CD99 pathways was observed between epithelial cells, T cells, and MCs in RCC. Conclusion: RCC harbors an immunosuppressive niche driven by T-cell exhaustion, MC reprogramming, and expansion of a malignant CASC15 + KLK6 + epithelial subpopulation. Targeting MIF and CD99 signaling networks represents a potential therapeutic strategy for RCC.


  • Open Access

    Quantitative analysis of peri-intestinal lymph node metastasis using indocyanine green fluorescence imaging technology

    by Weiyang Mm Lin, Qi Mm Li, Jie Sheng, Yibing Zhao, Wei Mm Cui

    We evaluated the efficacy of indocyanine green fluorescence imaging compared to that of traditional nanocarbon dyes in assessing peri-intestinal lymph node metastasis in patients with colorectal cancer, which is a key prognostic factor. The relationship between indocyanine green fluorescence imaging and histopathological outcomes in patients with colon cancer has also been explored. A retrospective analysis was conducted on 30 patients with colon cancer (from May to October 2023) confirmed by surgical pathology. Tumors were marked with indocyanine green (ICG) or nanocarbon via colonoscopy 16 to 24 hours before surgery. Within 15 minutes after surgery, peri-intestinal lymph node fluorescence imaging and hematoxylin and eosin staining were used to assess the distribution of cancer foci. The correlation between cancer foci distribution, fluorescence intensity, and area under the receiver operating characteristic curve was measured. Among 243 metastatic lymph nodes from 30 patients, 18 were found. After the patients were divided into metastatic and nonmetastatic groups, significant differences in tumor differentiation and stage were noted (P < .001). The fluorescence intensity was strongly correlated with the presence and proportion of metastasis (area under the receiver operating characteristic curve = 0.931), whereas nanocarbon staining showed no significant correlation (P = .81). All P values were two-sided, with P < .05 indicating statistical significance. Lymph nodes with malignant intestinal tumor metastasis displayed weaker ICG fluorescence than did nonmetastatic nodes. Combining ICG and nanocarbon staining techniques enhances intraoperative lymph node dissection and postoperative analysis, indicating their potential utility in colorectal cancer surgery.


  • Open Access

    Quantitative Analysis of Peri-intestinal Lymph Node Metastasis Using Indocyanine Green Fluorescence Imaging Technology

    by Weiyang Lin, Wei Cui, Qi Li, Jie Sheng, Yibing Zhao

    Objective: This study evaluates the efficacy of indocyanine green fluorescence imaging (ICG-FI) compared to traditional nanocarbon dye in assessing peri-intestinal lymph node metastasis in colorectal cancer, a key factor in prognosis. The relationship between ICG-FI and histopathological outcomes in colon cancer patients is also explored. Methods: A retrospective analysis was conducted on 30 colon cancer patients (May to October 2023), confirmed by surgical pathology. Tumors were marked with ICG or nanocarbon under colonoscopy 16-24 hours pre-surgery. Post-surgery, within 15 minutes, peri-intestinal lymph node fluorescence photography and hematoxylin and eosin staining assessed the cancer foci distribution. The study measured the correlation between cancer foci distribution, fluorescence intensity, and the area under the ROC curve (AUC). Results: Out of 243 metastatic lymph nodes from 30 patients, metastases were found in 18 nodes from 9 patients. Dividing patients into metastasis and non-metastasis groups, significant differences were noted in tumor differentiation and staging (p<0.001). Fluorescence intensity strongly correlated with metastasis presence and proportion (AUC=0.931), while nanocarbon staining showed no significant correlation (p=0.81). All p-values were two-sided, with p<0.05 indicating significance. Conclusion: Lymph nodes with malignant intestinal tumor metastasis displayed weaker ICG fluorescence compared to non-metastatic nodes. Combining ICG and nanocarbon staining techniques enhances intraoperative lymph node dissection and postoperative analysis, indicating their potential utility in colorectal cancer surgeries.